SAN DIEGO, Jan. 28, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits, which are intended to enable molecular laboratories around the world to utilize Biocept's Target Selector™ circulating tumor DNA (ctDNA) assays to perform liquid biopsy testing.  Biocept's Target Selector™ platform is patent protected in the United States and in 10 major international territories. The first available kit is for the high-sensitivity detection of EGFR oncogene mutations, which are among the most frequently evaluated biomarkers for lung cancer. Additional RUO test kits for other oncogene mutations are planned for launch in the future.

Biocept's Target Selector™ ctDNA platform utilizes patented primers, reagents, and methodologies to enrich the specimen for mutations of interest, resulting in very high assay sensitivity and specificity versus methods currently used in most laboratories.    

"The launch of our liquid biopsy kit strategy has been a priority for Biocept, and we are excited to now have the ability to leverage the value of our patents as we enable laboratories around the world to utilize our proprietary Target Selector technologies," said Michael Nall, President and CEO of Biocept. "Key objectives for this new business line are to create a leading global brand of research-use-only products, including kits and blood collection tubes, in the liquid biopsy market and to generate additional revenues in addition to those generated by our U.S.-based clinical laboratory business."

About Biocept's Target Selector™ ctDNA Kits

Target Selector™ liquid biopsy kits are marketed for research-use-only and utilize Biocept's proprietary and patented switch blocker technology to enable industry-leading sensitivity for the detection of mutations/variants of interest in ctDNA (one mutant copy in 10,000 wildtype DNA). These assays can be used on a variety of low-cost analytical platforms including qPCR, Sanger sequencing, microarrays, and mass-spectrometry, in addition to next generation sequencing. Target Selector™ kits offer high content per assay, which can reduce costs by amplifying multiple mutations/variants in hot-spot regions of interest in a single reaction. All ctDNA tests are quantitative.

The Biocept Target Selector™ EGFR Assay Kit is designed to perform testing for highly informative EGFR mutations that drive lung cancer including Del19, L858R, and T790M. For more information on Biocept's Target Selector™ liquid biopsy kits, or to order EGRF Assay Kits, please contact Biocept Customer Service at (888) 332-7729 or go to customerservice@biocept.com.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, our ability to broaden the use of our proprietary technology platform, our ability to launch additional test kits in the future, and our ability to generate additional revenues from the sale of test kits, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

SOURCE Biocept, Inc.

Related Links

https://biocept.com